Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Quentin30 is a pathological prevaricator.

<< Previous

Bullboard Posts

Next >>

Comment by Journeytcon Sep 17, 2024 7:56pm

87 Views

Post# 36228203

RE:RE:RE:RE:RE:Quentin30 is a pathological prevaricator.

I remember Brads 2016 presentation at the Richmond. Knives and forks clanging over his presentation. He spoke of reovirus as an activator for every biotherapeutic in development by major pharma. It was the first time ONC made any such disclosure. Exciting talk eight years ago. We are still waiting on ONC executing.

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide